GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (TSXV:MIR) » Definitions » LT-Debt-to-Total-Asset

MedMira (TSXV:MIR) LT-Debt-to-Total-Asset : 0.59 (As of Jan. 2024)


View and export this data going back to 1999. Start your Free Trial

What is MedMira LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MedMira's long-term debt to total assests ratio for the quarter that ended in Jan. 2024 was 0.59.

MedMira's long-term debt to total assets ratio declined from Jan. 2023 (0.69) to Jan. 2024 (0.59). It may suggest that MedMira is progressively becoming less dependent on debt to grow their business.


MedMira LT-Debt-to-Total-Asset Historical Data

The historical data trend for MedMira's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira LT-Debt-to-Total-Asset Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.93 0.57 0.54 0.81

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.79 0.81 0.64 0.59

MedMira LT-Debt-to-Total-Asset Calculation

MedMira's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

LT Debt to Total Assets (A: Jul. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Jul. 2023 )/Total Assets (A: Jul. 2023 )
=2.957/3.652
=0.81

MedMira's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (Q: Jan. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )/Total Assets (Q: Jan. 2024 )
=2.643/4.465
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (TSXV:MIR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


MedMira LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of MedMira's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (TSXV:MIR) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.